The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. This year’s metric has recorded a Price decrease of -93.80%. However, over the past six months, we’ve seen a stronger performance of -87.99%. The price of RNAZ leaped by -48.46% over the last 30 days. And in the last five days, it has fallen by -27.39%.
The stock price for TransCode Therapeutics Inc. (RNAZ) currently stands at $0.83. The stock experienced a substantial increase in the last session, hitting $0.9298 after starting at $0.91. The stock’s lowest price was $0.8651 before closing at $0.90.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
TransCode Therapeutics Inc. saw a rather unpredictable run in, in terms of market performance. The company’s stock reached its highest point at $31.00 on 10/26/22, while the lowest price for the same duration was marked at $0.85 on 09/11/23.
52-week price history of RNAZ Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. TransCode Therapeutics Inc.’s current trading price is -97.31% away from its 52-week high, while its distance from the 52-week low is -1.78%. The stock’s price range during this period has varied between$0.85 and $31.00. The TransCode Therapeutics Inc.’s shares, which operate in the Healthcare, saw a trading volume of around 5.27 million for the day, a figure considerably higher than their average daily volume of 0.15 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
TransCode Therapeutics Inc. (RNAZ) has experienced a quarterly decline of -69.86% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.87M and boasts a workforce of 19 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.2043, with a change in price of -6.1730. Similarly, TransCode Therapeutics Inc. recorded 240,440 in trading volume during the last 100 days, posting a change of -87.21%.
RNAZ’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for RNAZ stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
RNAZ Stock Stochastic Average
As of today, TransCode Therapeutics Inc.’s raw stochastic average for the last 50 days stands at 2.65%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 5.90%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 6.66% and 7.16%, respectively.
